HCP Live

1 day ago | hcplive.com | Lana Pine

Fatty liver disease is a growing public health crisis — yet it often remains undetected until catastrophic events force a diagnosis. Jerry Rosenberg’s story is a powerful reminder of this reality and offers key takeaways for physicians working at the intersection of primary care, hepatology, critical care, and transplant medicine.

2 days ago | hcplive.com | Tim Smith

An announcement by Nektar Therapeutics has revealed significant findings from the 16-week induction phase of the company's ongoing phase 2b REZOLVE-AD trial have been yielded regarding the investigational agent rezpegaldesleukin for atopic dermatitis.1Rezpegaldesleukin, a selective interleukin (IL)-pathway agonist designed to expand regulatory T cells (Tregs), was shown to be effective at 16 weeks among patients with moderate-to-severe atopic dermatitis.

3 days ago | hcplive.com | Mallory Locklear

Eating a high-fat diet will typically result in weight gain. But a new study published in Nature Metabolism has uncovered an unexpected biological loophole that turns fat storage into fat usage. In the study, mice became obese when consuming high-fat food, as expected.

4 days ago | hcplive.com | Tim Smith

A wide array of physicians, researchers, and industry leaders gathered in Nashville, Tennessee, to attend the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, a key meeting in the field of dermatology. Throughout the latest iteration of this yearly conference, late-breaking data that related specifically to atopic dermatitis.

4 days ago | hcplive.com | Patrick Campbell

Results of the phase 4 CATALYST trial indicate mifepristone (Korlym) significantly improved glycemic control, reduced body weight, and decreased waist circumference in patients with hypercortisolism and type 2 diabetes—offering a promising new strategy for a population with limited therapeutic success.